Enovis (ENOV)
(Real Time Quote from BATS)
$42.88 USD
-0.12 (-0.28%)
Updated Sep 10, 2024 09:48 AM ET
3-Hold of 5 3
B Value F Growth C Momentum C VGM
Price, Consensus and EPS Surprise
ENOV 42.88 -0.12(-0.28%)
Will ENOV be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ENOV based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ENOV
Enovis (ENOV) Introduces STAR Ankle With e+ Polyethylene
Enovis (ENOV) Q2 Earnings Top Estimates
ENOV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Standard BioTools (LAB) Reports Q2 Loss, Misses Revenue Estimates
Analysts Estimate Enovis (ENOV) to Report a Decline in Earnings: What to Look Out for
Should You Buy Hims & Hers (HIMS) Stock Ahead of Q2 Earnings?
Other News for ENOV
Enovis Appoints Tim Czartoski as President, U.S. Surgical and Global Product and Enabling Technologies
50 stocks that may see selling pressure as investors begin looking to book tax losses
Enovis? Introduces the Next Generation of Foot and Ankle Surgery Offerings at AOFAS Annual Meeting
Enovis to unveil Tarsoplasty Percutaneous Lapidus System at AOFAS Meeting
Diamond Hill Mid Cap Fund Q2 2024 Market Commentary